Regulatory Briefs: Consensus Standards; Penalty Amounts Increase; Biologics Center Seeks Branch Chief
This article was originally published in The Gray Sheet
Executive Summary
FDA adds 53 entries to the list of standards it will recognize for device pre-market submissions, and grants de novo approval for two device types. Civil money penalty amounts increase on inflation adjustment. The Center for Biologics Evaluation and Research searches for a review branch chief. More regulatory news.
You may also be interested in...
Classified: Next-Gen Sequencing Analyzers, Mobile Glucose Monitoring, Restless-Leg Devices
FDA issued orders officially finalizing regulatory classifications and special controls for next-generation sequencing analyzers; "secondary display" devices for continuous glucose monitor data; and vibratory counter-stimulation devices for restless leg syndrome. And the agency is working towards formalizing 510(k) exemptions for future devices of these types as well.
Regulatory Briefs: FDA Plans To Study Explanted Hips, Announces Upcoming Meetings
FDA is seeking applicants to help run an explant analysis study on hip implants. The agency plans a workshop on incorporating patient preference into CDRH regulatory decisions and a meeting with health professional organizations. More regulatory news.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”